Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

As of Thursday, May 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 5.79%, which has investors questioning if ...

Teos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

ITeos Therapeutics shares climbed after the company said it would evaluate strategic alternatives. The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

(Reuters) -iTeos Therapeutics and partner GSK said on Tuesday they have terminated development of their experimental lung ...